Global Life Science Instrumentation Market

Global Life Science Instrumentation Market Size, Share, Growth Analysis, By Technology(PCR, Spectroscopy), By Application(Clinical, Diagnostic), By Distribution Channel(Hospitals, Diagnostic Laboratories) - Industry Forecast 2024-2031


Report ID: SQMIG35A2512 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 101 | Figures: 76

Global Life Science Instrumentation Market Dynamics

Life Science Instrumentation Market Driver

  • Increased Government’s initiatives.

Increased government expenditure in life science research as well as rising R&D in the biotechnology and life science sectors are some of the key factors driving growth of the life science instrumentation market. Market expansion is further supported by greater food quality awareness and stringent government regulations to safeguard the safety of medicines. As per data released by the World Bank, spending in research and development made 2.63% of the global GDP in 2020. It has increased from 2019 which was 2.2% and is estimated to increase further in the forecasted years.

  • Increased Need for Analytical Instruments
    A growing focus on sequencing technology to understand the underlying causes of diseases is driving demand for analytical instruments. Moreover, the global life science instrumentation market is also experiencing need for user-friendly and sophisticated bioinformatics tools and the rapid development of emerging economies all contribute to the life science instrumentation market's significant potential. Moreover, as per studies globally, approximately one in three of all adults suffer from multiple chronic conditions (MCCs). This directly expands the requirement of testing and research which will grow the life sciences instrumentation market. As per reports, healthcare is one of the industries which receives maximum funds for research and development. In 2018, the R&D spend on healthcare was valued at around $169.5 billion.

Life Science Instrumentation Market Restraints

  • Lack of Skilled Professionals, High Costs Involved with Drug Discovery Process & Shortage of Funding In Emerging Economies

A shortage of skilled employees will lead to a decrease in innovation. A survey conducted by the Coalition of State Bioscience Institutes found that traditional manufacturing positions were the easiest functional roles to fill; the layoffs that occurred around the end of the previous year do indeed reflect an overstock of such workers. However, the issue of a skill set deficit still exists when it comes to the skill sets needed to manage biopharmaceutical manufacturing processes, particularly in the areas of engineering, data analytics, and process development.

This also seems to be more common in Europe life science instrumentation market, especially given the uncertainty surrounding Brexit. The UK was in "risk of losing its world-leading research and development reputation," according to the Association of the British Pharmaceutical Industry (ABPI), which was supported by the two largest pharmaceutical investors in the nation, AstraZeneca and GlaxoSmithKline, in February.

According to International Monetary Fund (IMF), there are 20 countries identified as emerging life science instrumentation market, and accounted for 34% of the world’s nominal GDP and 46% in purchasing-power-parity terms. The prevalence of chronic diseases is high in emerging countries, therefore the opportunity was research and expansion life science instrumentation is high but funding for R&D is comparatively less.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Life Science Instrumentation Market size was valued at USD 68.33 billion in 2019 and is poised to grow from USD 72.85 Billion in 2023 to USD 107.34 Billion by 2031, growing at a CAGR of 6.5% in the forecast period (2024-2031).

Key industry competitors in the life science instrumentation market are utilising market expansion tactics like acquisitions, mergers, and partnerships to broaden their product lines. Innovative technology and fresh product introductions have only been made by a select few companies. For example, NGS DreamPre, a fully automated method for next-generation sequencing (NGS), was introduced by Tecan Trading AG in February 2019. It produces quality-controlled, sequencing-ready NGS libraries in a matter of hours with no operator intervention or sample loss. The most popular business tactics utilised by market participants for expansion included product approval and launches, acquisition, collaborations, and agreements. For instance, due to its broad range of life science instrument products and associated accessories, Thermo Fisher Scientific, Inc. dominates the global life science instrumentation market. Through insight-driven innovation and strategic M&A, Thermo Fisher has increased the scope of its product offering to better position itself in the market. For example, throughout the previous few years. In addition to the Vanquish Duo UHPLC system, Scientific Q Exactive UHMR mass spectrometer, Ion GeneStudio S5 Series next-generation sequencing systems, and ISQ EC Single Quadrupole mass spectrometer, Thermo Fisher also released the Biosystems QuantStudio 6 and 7 Pro Real-Time PCR Systems in April 2019 and the ISQ EC Single Quadrupole mass spectrometer in February 2018. 'Thermo Fisher Scientific Inc.', 'Agilent Technologies Inc.', 'Danaher Corporation', 'PerkinElmer Inc.', 'Waters Corporation', 'Bruker Corporation', 'Becton, Dickinson and Company', 'Bio-Rad Laboratories Inc.', 'Illumina Inc.', 'Qiagen N.V.', 'F. Hoffmann-La Roche Ltd.', 'GE Healthcare', 'Shimadzu Corporation', 'Oxford Instruments plc', 'Hitachi High-Technologies Corporation', 'JEOL Ltd.', 'Carl Zeiss AG', 'Nikon Corporation', 'Leica Microsystems GmbH', 'Olympus Corporation'

Increased Government’s initiatives.

Use of Artificial Intelligence to automate laboratories and development of similar high-tech instruments. For example, recently Agilent Technologies Inc. (NYSE: A) announced that it had purchased advanced artificial intelligence (AI) technology created by Virtual Control, a maker of AI and machine learning software that develops cutting-edge analysis solutions for lab testing. The software, dubbed ACIES, will be incorporated by Agilent into its top-tier gas chromatography and mass spectrometry (GS/MS) platforms in order to boost the effectiveness, efficiency, and precision of the high-throughput labs that the business works with all over the world.

North America is expected to continue dominating the global life science instrumentation market during the projection period. The region has strong presence of food & beverage and pharmaceutical companies. Wherein, the product is used for testing of finished good for quality and safety testing. Thanks to the rising adoption of cutting-edge product introductions and technological developments, the region is enjoying higher market share. An important factor in the development of creative chemical methods in the area, which further propels the North American life science and chemical instruments market, has been the growing emphasis on the creation of new and enhanced drug assessment approaches to find highly complicated medications. For instance, Agilent unveiled the K6460S, a Class I medical device classified by the US Food and Drug Administration, in March 2020 as the next-generation clinical edition triple quadrupole LC/MS system. This technology is intended to enhance clinical lab workflows.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Life Science Instrumentation Market

Product ID: SQMIG35A2512

$5,300
BUY NOW GET FREE SAMPLE